At the forefront of therapies for rare and orphan diseasesTM
about us| programs| science & technology | patient advocacy | clinical studies | investors | collaborations | news & events

Home >> Investor Relations >> Investor Relations

Investor Relations

Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of therapies for rare and orphan diseases. The Company is developing novel, first-in-class treatments for a broad range of human genetic diseases, with a focus on delivering new benefits to individuals with lysosomal storage diseases. Amicus’ lead programs include the small molecule pharmacological chaperones migalastat HCl as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease; and AT2220 (duvoglustat HCl) in combination with ERT for Pompe disease.

View all »Recent Releases

Nov 24, 2014
Amicus Therapeutics Announces Closing of Underwritten Offering of Common Stock and Full Exercise of Over-Allotment Option

Nov 18, 2014
Amicus Therapeutics Prices Underwritten Offering of Common Stock

View all »Events & Presentations

Nov 15, 2014 at 10:00 AM ET
American Society of Nephrology (ASN) – Migalastat Monotherapy Phase 3 Data

Nov 6, 2014 at 5:00 PM ET
Amicus 3Q Results Conference Call and Webcast

Copyright © 2014 Amicus Therapeutics, Inc. All rights reserved.   Terms of Use | Privacy Policy